INFUMEDIUM SIGNALFINANCIAL10-K

INFU delivered strong operational performance with net income nearly tripling to $6.6M while simultaneously executing significant capital allocation through $9.9M in share buybacks and debt reduction.

The company appears to be in a much stronger financial position with improved profitability, cash generation, and balance sheet optimization. However, the 55% increase in interest expense despite debt reduction suggests potential refinancing at higher rates, which investors should monitor for impact on future profitability.

Comparing 2026-02-27 vs 2025-03-11View on EDGAR →
FINANCIAL ANALYSIS

INFU demonstrated robust financial improvement with net income surging 183% to $6.6M and operating cash flow growing 19% to $24.4M, enabling aggressive capital allocation through $9.9M in share buybacks (up 736%) and $4.3M in debt reduction. The company strengthened its balance sheet with cash increasing over 500% to $3.2M and inventory declining 17%, though current liabilities rose 14% and interest expense jumped 55% despite lower debt levels. Overall, the financial picture signals a company generating strong cash flows and actively returning capital to shareholders while optimizing its balance sheet structure.

FINANCIAL STATEMENT CHANGES
Share Buybacks
Cash Flow
+736.4%
$1.2M$9.9M

Share repurchases increased 736.4% — management returning capital, signals confidence in intrinsic value.

Cash & Equivalents
Balance Sheet
+504.6%
$527K$3.2M

Cash position surged 504.6% — strong cash generation or capital raise providing significant financial cushion.

Net Income
P&L
+182.6%
$2.3M$6.6M

Net income grew 182.6% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+73%
$6.9M$11.9M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Interest Expense
P&L
+54.8%
$1.4M$2.2M

Interest expense surged 54.8% — significant debt increase or rising rates materially impacting earnings.

Capital Expenditure
Cash Flow
-48.7%
$1.1M$560K

Capex reduced 48.7% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Operating Cash Flow
Cash Flow
+19.3%
$20.5M$24.4M

Operating cash flow grew 19.3% — strong conversion of earnings to cash, healthy business fundamentals.

Total Debt
Balance Sheet
-17.8%
$23.9M$19.6M

Debt reduced 17.8% — deleveraging strengthens balance sheet and reduces financial risk.

Inventory
Balance Sheet
-17.4%
$6.5M$5.4M

Inventory reduced 17.4% — lean inventory management or demand outpacing supply.

Current Liabilities
Balance Sheet
+14.3%
$17.7M$20.2M

Current liabilities rose 14.3% — increased short-term obligations, watch current ratio.

LANGUAGE CHANGES
NEW — 2026-02-27
PRIOR — 2025-03-11
ADDED
Many of the factors that will determine these items are beyond our ability to control or predict.
Our lead platform, Patient Services, provides last-mile solutions for clinic-to-home healthcare where the continuing treatment involves complex DME and related services.
Current barriers to entry for potential competitors are created by our: (i) growing number of third-party payer networks under contract, which included nearly 840 t hird-party payer networks as of December 31, 2025; (ii) economies of scale, which allow for predictable reimbursement and less costly purchase and management of the pumps, respectively; (iii) established, long-standing relationships as a provider of pumps to outpatient oncology practices in the U.S.
and Canada that allow for same-day or next-day delivery of pumps; (vi) our team of field-based and traveling biomedical technicians; and (vii) a wide array of pump repair and service capabilities.
In 2025, our Oncology Business generated approximately 87% of our total Patient Services segment net revenues.
+7 more — sign up free →
REMOVED
During the fiscal year ended December 31, 2023, the Company's also operated through its wholly-owned subsidiary First Biomedical, Inc., a Kansas Corporation, which merged into InfuSystem on January 1, 2024.
During the second quarter of 2023, the Company renamed its two operating segments.
Prior to that time, the Patient Services segment was known as Integrated Therapy Services and the Device Solutions segment was known as Durable Medical Equipment Services.
The changes were for marketing purposes only and there were no changes to the operations of either segment.
Our lead platform, Patient Services, provides last-mile solutions for clinic-to-home healthcare where the continuing treatment involves complex Durable Medical Equipment and related services.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →